Cognizant and Gilead sign a $800M agreement, expands partnership
JHVEPhoto         Cognizant (NASDAQ:CTSH) expands relationship withÂ Gilead Sciences (NASDAQ:GILD) to renew and expand services to the biotech for a total expected value of $800M over the next five years.
This collaboration is aimed at enabling Gilead to streamline various parts of its business with the goal of faster time to market of various medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer.
ItÂ includes supporting enabling technologies for running business operations, new product launches and improving IT processes for efficient research, manufacturing, and commercialization of its products.